Lina Chen | Plant Biotechnology | Best Researcher Award

Prof. Lina Chen | Plant Biotechnology | Best Researcher Award

School of Basic Medical Sciences, Xi’an Jiaotong University | China

Author Profile

Orcid ID

LINA CHEN: A LEADING EXPERT IN ENDOCRINE AND CARDIOVASCULAR PHARMACOLOGY 🌱

📚 EARLY ACADEMIC PURSUITS

Lina Chen began her academic journey in 1992 at Xi’an Medical University, where she pursued a Bachelor of Medicine in Preventive Medicine. Her commitment to pharmacology led her to Xi’an Jiaotong University, where she completed her MSc in Pharmacology (2003) and later, a PhD in the same field (2006). These formative years laid the foundation for her distinguished career in pharmacology and medical sciences.

🧪 PROFESSIONAL ENDEAVORS

After obtaining her PhD, Lina Chen worked as a Lecturer in the Department of Pharmacology at Xi’an Jiaotong University (2006-2013). Her academic journey continued with an Associate Professorship (2013-2017) and eventually to the position of Professor (2018-present). Her career was also enriched by an international collaboration as a Visiting Scholar at the University of Nebraska Medical Center in 2009-2010, strengthening her global research network.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PLANT BIOTECHNOLOGY

Professor Chen is renowned for her work in endocrine and cardiovascular pharmacology, specifically focusing on the pathogenesis, drug screening, prevention, and treatment of diabetes and metabolic diseases. She has led numerous high-profile research projects, including national programs such as the National Major New Drug Development Project and the National Natural Science Foundation of China. Her research has a significant impact on understanding and combating chronic diseases, particularly in the context of Chinese and global health challenges.

🌍 IMPACT AND INFLUENCE

Professor Chen’s groundbreaking work has influenced both academic research and practical healthcare solutions. She has contributed extensively to medical literature, with over 80 published articles, including 40 SCI papers. Her 7 national invention patents showcase her innovation in pharmacological treatments and drug development, cementing her reputation as a thought leader in her field. Her work is integral to the development of novel drugs and therapeutic strategies.

📈 ACADEMIC CITATIONS AND PUBLICATIONS

With an impressive Citation Index of 831, Professor Chen’s research has been widely recognized within the scientific community. Her work has been published in top-tier journals and included in more than 40 books. Her contributions have earned her recognition as a key player in pharmacological research. Professor Chen has also been an editorial board member for several prestigious journals, influencing scientific publication and policy.

🏅 HONORS & AWARDS

  • Second Prize of Science and Technology Progress from Shaanxi Province
  • National Invention Patents (7 patents)
  • Various Research Grants and Fellowships, including those from the National Natural Science Foundation of China and the Provincial Key Projects.

🌐 LEGACY AND FUTURE CONTRIBUTIONS

Professor Chen‘s career is characterized by her unwavering commitment to public health, groundbreaking research, and innovative contributions to pharmacology. Looking ahead, her ongoing research will continue to shape the landscape of diabetes treatment and cardiovascular health, providing new hope for millions worldwide. Her future contributions are expected to be instrumental in furthering both scientific discovery and the practical application of pharmacological therapies.

🌠 FINAL NOTE

Professor Lina Chen continues to advance the field of pharmacology with a focus on diabetes and cardiovascular diseases. Her research excellence and innovative drug developments promise to leave a lasting legacy in both academia and global healthcare. With a clear vision for the future, she remains a leading voice in the pursuit of medical solutions for metabolic diseases.

📑 NOTABLE PUBLICATIONS 

Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
  • Journal: Molecular Medicine (Cambridge, Mass.)
  • Date: 2023-09-28
  • Authors: Guo T, Yan W, Cui X, Liu N, Wei X, Sun Y, Fan K, Liu J, Zhu Y, Wang Z et al.
Corrigendum to “Erythropoietin ameliorates cognitive deficits by improving hippocampal and synaptic damage in streptozotocin-induced diabetic mice” [Cellular Signalling 106 (2023) 110614].
  • Journal: Cellular Signalling
  • Date: 2023-09-09
  • Authors: Yan W, Guo T, Liu N, Cui X, Wei X, Sun Y, Hu H, Chen L
Erythropoietin ameliorates cognitive deficits by improving hippocampal and synaptic damage in streptozotocin-induced diabetic mice.
  • Journal: Cellular Signalling
  • Date: 2023-09-06
  • Authors: Yan W, Guo T, Liu N, Cui X, Wei X, Sun Y, Hu H, Chen L
Mollugin activates GLP-1R to improve cognitive dysfunction in type 2 diabetic mice.
  • Journal: Life Sciences
  • Date: 2023-08-21
  • Authors: Wang Z, Cui X, Yan W, Liu N, Shang J, Yi X, Guo T, Wei X, Sun Y, Hu H et al.
Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion.
  • Journal: Molecular and Cellular Endocrinology
  • Date: 2023-07-24
  • Authors: Shang J, Yan W, Cui X, Ma W, Wang Z, Liu N, Yi X, Guo T, Wei X, Sun Y et al.

 

Arthur M. Feldman | Medicinal Plants | Best Researcher Award

Dr. Arthur M. Feldman | Medicinal Plants | Best Researcher Award

Lewis Katz School of Medicine at Temple University | United States

Author Profile

🌟Arthur M. Feldman, MD, PhD: A Legacy of Excellence in Cardiology

📚 EARLY ACADEMIC PURSUITS

Arthur M. Feldman, MD, PhD, embarked on his illustrious academic journey with a foundation in biology at Gettysburg College, where he earned a Bachelor of Arts in 1970. His pursuit of scientific excellence continued with a Master’s degree in Zoology (1973) and a Ph.D. in Physiology (1974) from the University of Maryland, College Park. Driven by a passion for understanding human physiology, he later achieved his MD from LSU School of Medicine in Shreveport in 1981, setting the stage for his impactful career in medicine.

🧪 PROFESSIONAL ENDEAVORS

Dr. Feldman’s career spans decades of distinguished service in academia, research, and clinical practice. Beginning as a Graduate Teaching Assistant at the University of Maryland, he rose through the ranks, holding prestigious positions such as Director of Heart Failure Research at Johns Hopkins and Chief of the Division of Cardiology at the University of Pittsburgh. His leadership extended to serving as Executive Dean at Temple University’s School of Medicine and as the Laura H. Carnell Professor of Medicine. He also demonstrated entrepreneurial acumen by founding companies like Cardiokine, Inc., and Renovacor, Inc., contributing to advancements in cardiac care.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON MEDICINAL PLANTS

Dr. Feldman’s research has profoundly shaped the understanding of heart failure, particularly in receptor-G protein signaling and matrix metalloproteinases. His innovative studies on G protein function in heart failure illuminated pathways for therapeutic interventions, while his work on metalloproteinases offered groundbreaking insights into cardiac remodeling. With over 400 manuscripts, 50 textbook chapters, and four books to his name, his scholarly contributions have earned him an H-index of 93 and more than 86,000 citations.

🌍 IMPACT AND INFLUENCE

As a pioneer in cardiology, Dr. Feldman’s influence extends beyond research. He has trained countless professionals, contributed to seminal guidelines on heart failure management, and played leadership roles in organizations like the Heart Failure Society of America and the American Heart Association. His editorial work for journals like Clinical and Translational Science has further solidified his standing as a thought leader.

📈 ACADEMIC CITATIONS AND PUBLICATIONS

Dr. Feldman’s academic output is monumental, with key publications that have advanced the fields of heart failure and cardiac physiology. Notable works include studies on adrenergic signaling in failing hearts and the role of metalloproteinases in cardiac remodeling. These publications have shaped clinical practices and fostered new research directions.

🏅 HONORS & AWARDS

Dr. Feldman’s contributions have been recognized with numerous accolades:

  • Lewis Gottlieb Scholar Award (1981)
  • Distinguished Alumnus Award, Gettysburg College (1995)
  • Lifetime Achievement Award, Heart Failure Society of America (2013)
  • Distinguished Scientist Award, American College of Cardiology (2019)
  • Senior Member, National Academy of Inventors (2023)

His consistent inclusion in “Best Doctors in America” reflects his enduring impact on the field.

🌐 LEGACY AND FUTURE CONTRIBUTIONS

As Dr. Feldman continues to contribute to the field through mentorship, research, and innovation, his legacy serves as an inspiration to future generations. His pioneering efforts in cardiology ensure a lasting impact on medical science and patient care.

🌠 FINAL NOTE

Dr. Feldman’s career exemplifies the fusion of academic rigor, clinical expertise, and innovative thinking. His work has not only advanced medical knowledge but also improved the lives of countless patients.

📑 NOTABLE PUBLICATIONS 

The Role of BAG3 Protein Interactions in Cardiomyopathies
  • Authors: Qu, H.-Q., Wang, J.-F., Rosa-Campos, A., Hakonarson, H., Feldman, A.M.
  • Journal: International Journal of Molecular Sciences
  • Year: 2024
Rare variants in cardiomyopathy genes predispose to cardiac injury in severe COVID-19 patients of African or Hispanic ancestry
  • Authors: Qu, H.-Q., Delfiner, M.S., Gangireddy, C., Hakonarson, H., Feldman, A.M.
  • Journal: Journal of Molecular Medicine
  • Year: 2024
Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380S BAG3 Variants
  • Authors: Martin, T.G., Pak, H., Gerhard, G.S., Feldman, A.M., Kirk, J.A.
  • Journal: Journal of the American Heart Association
  • Year: 2023
Bag3 Regulates Mitochondrial Function and the Inflammasome Through Canonical and Noncanonical Pathways in the Heart
  • Authors: Wang, J., Tomar, D., Martin, T.G., Kirk, J.A., Feldman, A.M.
  • Journal: JACC: Basic to Translational Science
  • Year: 2023
Precision Medicine: Solving the Mystery of Myocarditis in the Aftermath of SARS-CoV-2
  • Authors: Feldman, A.M., Kasper, E.K., Qu, H.-Q.
  • Journal: JACC: Heart Failure
  • Year: 2023